Zdv Ppt - Final

8/16/2019 Zdv Ppt - Final

1/18

Correlation of Mean Corpuscular Volume and H

toZidovudine-induced Anemia in Patients UndHighly Active Antiretroviral Therapy at the

!nstitute for Tropical Medicine


2/18

"ac#ground of the $tudy

Zidovudine (ZDV) is a frst-line drug used in antiretroviral therapy (ART

One o the most severe side eets o ZDV inta!e is anemia

A"out #-$% o patients ta!ing ZDV develop anemia

&atients 'ith ZDV in their therapy are at more ris! o developing anem

patients 'ithout ZDV in their therapy


3/18

emoglo"in is the only parameter onsidered or ZDV initia

&revious studies have suggested that a lo' *V may "e mprediting the ris! o ZDV-indued anemia


4/18

%eneral &b'ective

To determine i the hemoglo"in and *V is orrelated "eore and ater treatment o ZDV+

$peci(c &b'ectives To determine i hemoglo"in and *V o patient "eore treatment is orrel

hemoglo"in and *V o those 'hih developed anemia

To determine i hemoglo"in and *V o patient "eore treatment is orrelhemoglo"in and *V o those 'hih did not develop anemia


5/18

$igni(cance of the $tudy

&reventing anemia in ,V patients is espeially important to high survival rate+

ethods to replenish "lood is epensive+

Additional relevant parameters or saely reommending ZDpatients are needed+


6/18

$cope and )imitation

$cope This study oused on the *V o the ,V patients undergoin

ZDV inta!e+

)imitations

All data is gathered rom the Researh ,nstitute or Tropial The data o"tained spanned rom .anuary $/#0 to .anuary $/

2u"3ets had ZDV inluded in their therapy

2u"3ets have at least one ollo' up 'ithin the si months a


7/18

Methodology

,nlusion *riteria

#4 years old and a"ove

ale and emale

Treatment na5ve 6ndergoing AART or the frst time

as used ZDV

as at least one ollo' up 'ithin 1months o treatment

Alive 'ithin 1 months o treatment

.anuary $/#0 7 .anuary $/#1

8lusion *riteria

Aged "elo

Did not have at least one ollo'ithin 1 months o treatm

Already undergone A 6ndergone "lood transusion $ '

"eore start o the

Ta!ing o

Ta!ing o drugs that may indue an

Died 'ithin 1 months o A

;ot reorded 'ithin 1 months rom

start o A


8/18

Methodology


9/18

$tatistical Tests

,


10/18

esults

Before Treatment After Treatment

HGB MCV HGB MCV

Before

Treatment

HGB - - 0.199 0.665 0.227

MCV -0.199 - 0.065 0.858*

After

Treatment HGB 0.665 0.065 - 0.415

MCV 0.227 0.858* 0.415 -

Table *+ *orrelation o hemoglo"in and *V "eore andater treatment o ZDV o patients 'ho did not developanemia>r ? /+404@ p , +.


11/18

esults

Before

Treatment

After Treatment

HGB MCV HGB MCV

Before

Treatment

HGB - 0.004 0.774* -0.177

MCV 0.004 - -0.311 0.774*

After Treatment

HGB 0.774* -0.311 - -0.417

MCV -0.177 0.774* -0.417 -

Table /+ *orrelation o hemoglo"in and *V "eore andater treatment o ZDV o patients 'ho developedanemia>r ? /+404@ p , +*


12/18

Conclusion

emoglo"in and *V are not aurate in assessing ZDV-inin ,V patients undergoing AART involving ZDV+


13/18

ecommendations

arger sample siBe

onger period duration period or sampling

*onsider other parameters andCor tests to orrelate 'ith the ourro ZDV-indued anemia in ,V patients undergoing treatment 'ith Z


14/18

TA; EO6

Antio3o@ Reno .ohn RenBy

*hua@ Tyhius

*hua@ VannesBa endri!e

*ollado@ .ohn .oe"ert

.usto@ .an artin

ateos@ a+ 8loisa *arla

&angan@ eryl ouis

2y@ 2amantha ope

F*T


15/18

Reerenes

Adediran@ A+@ Osun!alu@ V+@ Ga!ama@ T+@ .ohn-Ola"ode@ 2+@ A!in"ami@ A+@ 6he@ 8+@ H

A!anmu@ 2+ ($/#1)+ ,mpat o ,V ,netion and Zidovudine Therapy on R


16/18

Reerenes

*laster@ 2+ ($//$)+


17/18

Reerenes 8poetin ala (R)


18/18

Reerenes 2harma@ 2+ ($/#/)+ Zidovudine-indued anaemia in ,VCA,D2+ ,ndian .ournal o

edial Researh@ #N$@ N0-N1#+ Retrieved :e"ruary #0@ $/#1+

2uma@ +@ 2esan!@ R+@ Vidyasagar@ +@ H 2atyanarayana@ + ($/#0)+ ematologial parameters in ,V su"3ets on Zidovudine Therapy+ &erspetives in edial

Researh@ N($)@ ##-#F+ Retrieved :e"ruary #0@ $/#1+

Tadele@ A+@ edir@ A+@ 8na'ga'@

Documents

Zdv Ppt - Final